nach oben

Current Atherosclerosis Reports

Erschienen in:

01.06.2021 | Vascular Biology (H. Pownall, Section Editor)

Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia

verfasst von: Joan Carles Escolà-Gil, Noemí Rotllan, Josep Julve, Francisco Blanco-Vaca

Erschienen in: Current Atherosclerosis Reports | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We seek to establish whether high-density lipoprotein HDL metabolism and reverse cholesterol transport (RCT) impairment is an intrinsic feature of familial hypercholesterolemia (FH).

Recent Findings

RCT from macrophages (m-RCT), a vascular cell type of major influence on atherosclerosis, is impaired in FH due to defective low-density lipoprotein receptor (LDLR) function via both the HDL- and LDL-mediated pathways. Potential mechanisms include impaired HDL metabolism, which is linked to increased LDL levels, as well as the increased transport of cellular unesterified cholesterol to LDL, which presents a defective catabolism.

Summary

RCT dysfunction is consistently associated with mutation-positive FH linked to decreased HDL levels as well as impaired HDL remodeling and LDLR function. It remains to be explored whether these alterations are also present in less well-characterized forms of FH, such as cases with no identified mutations, and whether they are fully corrected by current standard treatments.

Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–3490a.PubMedPubMedCentralCrossRef

Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013;381(9874):1293–301.PubMedCrossRef

3.•

Martin-Campos JM, Ruiz-Nogales S, Ibarretxe D, et al. Polygenic markers in patients diagnosed of autosomal dominant hypercholesterolemia in catalonia: distribution of weighted LDL-c-raising SNP scores and refinement of variant selection. Biomedicines. 2020;8(9):353. In line with previous findings of different groups, the increased LDL genetic score based on selected SNPs in mutation-negative FH patients suggest the existence of polygenic forms of the disease.

4.••

Kontush A. HDL and reverse remnant-cholesterol transport (RRT): Relevance to cardiovascular disease. Trends Mol Med. 2020;26(12):1086–100. This review proposes a potential novel pathway that explains the U-shaped relationship between plasma HDL-C levels and cardiovascular disease via the impairment of the transfer of unesterified cholesterol from triglyceride-rich lipoproteins to HDL.PubMedCrossRef

5.••

Rosales C, Gillard BK, Xu B, Gotto AM Jr, Pownall HJ. Revisiting reverse cholesterol transport in the context of high-density lipoprotein free cholesterol bioavailability. Methodist Debakey Cardiovasc J. 2019;15(1):47–54. This review hypothesizes that an increased bioavailability of unesterified cholesterol in dysfunctional HDL would promote the excess transfer of this molecule to cells, thus constituting a potential proatherogenic mechanism.PubMedPubMedCentralCrossRef

Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256(6):482–90.PubMedCrossRef

van Aalst-Cohen ES, Jansen AC, Boekholdt SM, et al. Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. Eur J Hum Genet. 2005;13(10):1137–42.PubMedCrossRef

Inazu A, Koizumi J, Mabuchi H, Kajinami K, Takeda R. Enhanced cholesteryl ester transfer protein activities and abnormalities of high density lipoproteins in familial hypercholesterolemia. Horm Metab Res. 1992;24(6):284–8.PubMedCrossRef

Bellanger N, Orsoni A, Julia Z, Fournier N, Frisdal E, Duchene E, et al. Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2011;31(7):1675–81.PubMedCrossRef

10.•

Badimon L, Padro T, Cubedo J. Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia: implications in cardiovascular disease manifestation and outcome. Curr Opin Lipidol. 2017;28(5):427–33. This review focuses on the identification of HDL protein changes that might contribute to the increased cardiovascular risk of familial hypercholesterolemia.PubMedCrossRef

11.

Hogue JC, Lamarche B, Gaudet D, Tremblay AJ, Després JP, Bergeron J, et al. Association of heterozygous familial hypercholesterolemia with smaller HDL particle size. Atherosclerosis. 2007;190(2):429–35.PubMedCrossRef

12.

Hussein H, Saheb S, Couturier M, Atassi M, Orsoni A, Carrié A, et al. Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis. J Clin Lipidol. 2016;10(1):124–33.PubMedCrossRef

13.

Koizumi J, Inazu A, Fujita H, et al. Removal of apolipoprotein E-enriched high density lipoprotein by LDL-apheresis in familial hypercholesterolaemia: a possible activation of the reverse cholesterol transport system. Atherosclerosis. 1988;74(1-2):1–8.PubMedCrossRef

14.••

Cedo L, Plana N, Metso J, et al. Altered HDL remodeling and functionality in familial hypercholesterolemia. J Am Coll Cardiol. 2018;71(4):466–8. Short communication showing impairment in lipid transfer proteins and enzymes regulating HDL remodeling and cholesterol efflux in untreated heterozygous patients with an LDLR identified mutation.PubMedCrossRef

15.

Miida T, Nakamura Y, Okada M. Development of coronary atherosclerosis in asymptomatic heterozygous patients with familial hypercholesterolemia. J Cardiol. 1996;28(2):71–7.PubMed

16.

Frenais R, Ouguerram K, Maugeais C, et al. Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study. J Lipid Res. 1999;40(8):1506–11.PubMedCrossRef

17.

Schaefer JR, Rader DJ, Ikewaki K, Fairwell T, Zech LA, Kindt MR, et al. In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia. Arterioscler Thromb. 1992;12(7):843–8.PubMedCrossRef

18.

Gibson JC, Goldberg RB, Rubinstein A, Ginsberg HN, Brown WV, Baker S, et al. Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia. Arteriosclerosis. 1987;7(4):401–7.PubMedCrossRef

19.

Miltiadous G, Cariolou MA, Elisaf M. HDL cholesterol levels in patients with molecularly defined familial hypercholesterolemia. Ann Clin Lab Sci. 2002;32(1):50–4.PubMed

20.

Cubedo J, Padro T, Alonso R, Mata P, Badimon L. ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia. J Lipid Res. 2016;57(6):1059–73.PubMedPubMedCentralCrossRef

21.

Swertfeger DK, Rebholz S, Li H, Shah AS, Davidson WS, Lu LJ. Feasibility of a plasma bioassay to assess oxidative protection of low-density lipoproteins by high-density lipoproteins. J Clin Lipidol. 2018;12(6):1539–48.PubMedPubMedCentralCrossRef

22.••

Cedo L, Metso J, Santos D, et al. LDL receptor regulates the reverse transport of macrophage-derived unesterified cholesterol via concerted action of the HDL-LDL axis: insight from mouse models. Circ Res. 2020;127(6):778–92. In vivo demonstration of impaired m-RCT in mouse models of familial hypercholesterolemia due to major LDLR dysfunction, but not in models with a similar phenotype but conserved LDLR capacity, such as the apoB100 transgenic mice.PubMedCrossRef

23.

Lakomy D, Rebe C, Sberna AL, et al. Liver X receptor-mediated induction of cholesteryl ester transfer protein expression is selectively impaired in inflammatory macrophages. Arterioscler Thromb Vasc Biol. 2009;29(11):1923–9.PubMedCrossRef

24.

Laffitte BA, Joseph SB, Chen M, Castrillo A, Repa J, Wilpitz D, et al. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol Cell Biol. 2003;23(6):2182–91.PubMedPubMedCentralCrossRef

25.

Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383–93.PubMedPubMedCentralCrossRef

26.

Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3(7):507–13.PubMedPubMedCentralCrossRef

27.

Ottestad IO, Halvorsen B, Balstad TR, Otterdal K, Borge GI, Brosstad F, et al. Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux. J Nutr. 2006;136(4):877–81.PubMedCrossRef

28.

Ogura M, Hori M, Harada-Shiba M. Association between cholesterol efflux capacity and atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2016;36(1):181–8.PubMedCrossRef

29.••

Soria-Florido MT, Schroder H, Grau M, Fito M, Lassale C. High density lipoprotein functionality and cardiovascular events and mortality: a systematic review and meta-analysis. Atherosclerosis. 2020;302:36–42. Systematic review and meta-analysis showing that although increased HDL cholesterol efflux capacity and antioxidant/anti-inflammatory capacities are associated with a lower risk of cardiovascular disease, there is a need of larger prospective studies with predefined standardized assays and outcomes.PubMedCrossRef

30.

Guerin M, Silvain J, Gall J, Darabi M, Berthet M, Frisdal E, et al. Association of serum cholesterol efflux capacity with mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2018;72(25):3259–69.PubMedCrossRef

31.••

von Eckardstein A. LDL contributes to reverse cholesterol transport. Circ Res. 2020;127(6):793–5. Insightful editorial comment on the role of LDL on CEC measurements and on the potential significance of unesterified cholesterol transfer from HDL to LDL in atherogenesis.CrossRef

32.

Guerin M, Dolphin PJ, Chapman MJ. Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler Thromb. 1994;14(5):679–85.PubMedCrossRef

33.••

Feng M, Darabi M, Tubeuf E, et al. Free cholesterol transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis underlies the U-shape relationship between HDL-cholesterol and cardiovascular disease. Eur J Prev Cardiol. 2020;27(15):1606–16. Study revealing that unesterified cholesterol transfer to HDL is linked to triglyceride-rich lipoprotein lipolysis and parallels the U-shape relationship between HDL-C and cardiovascular disease.PubMedCrossRef

34.

Sankaranarayanan S, de la Llera-Moya M, Drazul-Schrader D, Phillips MC, Kellner-Weibel G, Rothblat GH. Serum albumin acts as a shuttle to enhance cholesterol efflux from cells. J Lipid Res. 2013;54(3):671–6.PubMedPubMedCentralCrossRef

35.

Mosig S, Rennert K, Buttner P, et al. Monocytes of patients with familial hypercholesterolemia show alterations in cholesterol metabolism. BMC Med Genet. 2008;1:60.

36.

Canfran-Duque A, Lin CS, Goedeke L, Suarez Y, Fernandez-Hernando C. Micro-RNAs and high-density lipoprotein metabolism. Arterioscler Thromb Vasc Biol. 2016;36(6):1076–84.PubMedPubMedCentralCrossRef

37.

Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13(4):239–50.PubMedPubMedCentralCrossRef

38.

Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13(4):423–33.PubMedPubMedCentralCrossRef

39.

Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.PubMedCrossRef

40.

Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92–105.PubMedPubMedCentralCrossRef

41.

Wang L, Jia XJ, Jiang HJ, du Y, Yang F, Si SY, et al. MicroRNAs 185, 96, and 223 repress selective high-density lipoprotein cholesterol uptake through posttranscriptional inhibition. Mol Cell Biol. 2013;33(10):1956–64.PubMedPubMedCentralCrossRef

42.

Vickers KC, Landstreet SR, Levin MG, Shoucri BM, Toth CL, Taylor RC, et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci U S A. 2014;111(40):14518–23.PubMedPubMedCentralCrossRef

43.

Martino F, Carlomosti F, Avitabile D, Persico L, Picozza M, Barillà F, et al. Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age. Clin Sci (Lond). 2015;129(11):963–72.CrossRef

44.•

D'Agostino M, Martino F, Sileno S, et al. Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a/b levels: implication of a ZEB1-dependent mechanism. Clin Sci (Lond). 2017;131(18):2397–408. Study showing that circulating miR-200c is upregulated in pediatric FH, probably due to oxidative stress and inflammation and via a miR-33a/b-ZEB1-dependent mechanism.CrossRef

45.

Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328(5985):1570–3.PubMedPubMedCentralCrossRef

46.

Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328(5985):1566–9.PubMedCrossRef

47.

Marquart TJ, Allen RM, Ory DS. Baldan A: miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A. 2010;107(27):12228–32.PubMedPubMedCentralCrossRef

48.

Rinninger F, Heine M, Singaraja R, Hayden M, Brundert M, Ramakrishnan R, et al. High density lipoprotein metabolism in low density lipoprotein receptor-deficient mice. J Lipid Res. 2014;55(9):1914–24.PubMedPubMedCentralCrossRef

49.

Tanigawa H, Billheimer JT, Tohyama J, Zhang Y, Rothblat G, Rader DJ. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation. 2007;116(11):1267–73.PubMedCrossRef

50.

Le May C, Berger JM, Lespine A, et al. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler Thromb Vasc Biol. 2013;33(7):1484–93.PubMedCrossRef

51.

Orsoni A, Saheb S, Levels JH, et al. LDL-apheresis depletes apoE-HDL and pre-beta1-HDL in familial hypercholesterolemia: relevance to atheroprotection. J Lipid Res. 2011;52(12):2304–13.PubMedPubMedCentralCrossRef

52.

Orsoni A, Villard EF, Bruckert E, Robillard P, Carrie A, Bonnefont-Rousselot D, et al. Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia. J Lipid Res. 2012;53(4):767–75.PubMedPubMedCentralCrossRef

53.••

Tao H, Huang J, Yancey PG, et al. Scavenging of reactive dicarbonyls with 2-hydroxybenzylamine reduces atherosclerosis in hypercholesterolemic Ldlr(-/-) mice. Nat Commun. 2020;11(1):4084. Treatment of FH mice with reactive dicarbonyl scavengers reduced HDL oxidative modification and increased HDL cholesterol efflux capacity; HDL from subjects with FH had increased MDA-apoAI adducts and defective cholesterol efflux capacity.PubMedPubMedCentralCrossRef

54.

Yahya R, Favari E, Calabresi L, Verhoeven AJM, Zimetti F, Adorni MP, et al. Lomitapide affects HDL composition and function. Atherosclerosis. 2016;251:15–8.PubMedCrossRef

55.

Lappegard KT, Kjellmo CA, Ljunggren S, et al. Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study. Transfus Apher Sci. 2018;57(1):91–6.PubMedCrossRef

56.

Adorni MP, Cipollari E, Favari E, Zanotti I, Zimetti F, Corsini A, et al. Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis. 2017;256:1–6.PubMedCrossRef

57.••

Christensen JJ, Ulven SM, Retterstol K, et al. Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: a cross-sectional study. Atherosclerosis. 2017;266:48–57. Interesting study showing that the NMR plasma analysis of children uncovers major changes in FH HDL.PubMedCrossRef

58.

Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, Uehara Y, et al. Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet. Arterioscler Thromb Vasc Biol. 2014;34(10):2246–53.PubMedCrossRef

59.

Tardy C, Goffinet M, Boubekeur N, Ackermann R, Sy G, Bluteau A, et al. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis. 2014;232(1):110–8.PubMedCrossRef

60.

Hovingh GK, Smits LP, Stefanutti C, Soran H, Kwok S, de Graaf J, et al. The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study. Am Heart J. 2015;169(5):736–42 e731.PubMedCrossRef

61.

Zheng KH, Kaiser Y, van Olden CC, Santos RD, Dasseux JL, Genest J, et al. No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. Atherosclerosis. 2020;311:13–9.PubMedCrossRef

Titel: Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia
verfasst von: Joan Carles Escolà-Gil
Noemí Rotllan
Josep Julve
Francisco Blanco-Vaca
Publikationsdatum: 01.06.2021
Verlag: Springer US
Erschienen in: Current Atherosclerosis Reports / Ausgabe 6/2021
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-021-00928-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

17.04.2024 | DGIM 2024 | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents

The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes

Metabolomic Biomarkers of Healthy Dietary Patterns and Cardiovascular Outcomes

How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?

Food Insecurity and Cardiovascular Disease Risk

Understanding Immigration as a Social Determinant of Health: Cardiovascular Disease in Hispanics/Latinos and South Asians in the United States

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin